Author:
Lehmann Matthieu,Pouly Jean-Luc,Barrière Paul,Boland Lauren Amy,Bean Samuel George,Jenkins Julian
Reference15 articles.
1. Comparative effectiveness of gonadotropins used for ovarian stimulation during assisted reproductive technologies (ART) in France: a real-world observational study from the French nationwide claims database (SNDS);Grynberg;Best Pract Res Clin Obstet Gynaecol,2023
2. A real-world study of ART in France (REOLA) comparing a biosimilar rFSH against the originator according to rFSH starting dose;Barrière;J Gynecol Obstet Hum Reprod,2023
3. Reply to the letter to the editor in response to ‘A real-world study of ART in France (REOLA) comparing a biosimilar rFSH against the originator according to rFSH starting dose’ by S. Montenegro, C. Helwig, J.-E. Schwarze, C. Castello-Bridoux, S. Marque, M. Lispi, et al. (J Gynecol Obstet Hum Reprod. 2023;52(8):102640)
4. 'Model' versus 'everyday' patients: can randomized controlled trial data really be applied to the clinic?;Hershkop;Reprod Biomed Online,2017
5. A cost-effectiveness analysis comparing the originator follitropin alfa to its biosimilars in patients undergoing a medically assisted reproduction program from a French perspective;Grynberg;J Med Econ,2018